Clinical research has shown that recurrence of Mantle Cell Lymphoma, a variant of malignant lymphoma, can be reduced by almost 50% in patients who receive maintenance treatment with the antibody rituximab. These results are presented by Dr Hanneke Kluin-Nelemans at the 16th Congress of the European Hematology Association in London. Mantle cell lymphoma represents a variant of malignant lymphoma (lay term for lymph node cancer). The disease characteristically affects people above 60 years. Multiple lymph nodes, bone marrow, spleen, and blood are often involved... 
More...
More...